Http://www2.smartbrief.com/servlet/wireless?issueid=0942e7fc-7106-4e12-86cc-4511734432b7&sid=a50d4a85%2d51f0%2d424b%2d886c%2dec3a716b9d75

Your feedback is important to us. email us your feedback.
Digestive Health SmartBrief
April 5, 2013
Patient Perspectives
Patient's perspective
"We can all agree that inflammatory bowel disease is an isolating and painful disease.
Unfortunately, many people don’t want to talk about it because there is a ton of stigma attached to one of the most prevalent symptoms of Crohn’s and colitis which is frequent diarrhea." Blog post by Christina on Top Story
Course helps patients follow gluten-free diet, study finds
Adults with celiac disease who participated in a six-week online course did a better job following a gluten-free diet than those who did not get the intervention, according to a University of Sydney study in the American Journal of Gastroenterology. The course included patient education about eating gluten-free, and techniques for behavior modification and Guide to Healthy Living
Study links antihistamines to higher risk of C. difficile infection
An analysis of 33 studies showed that patients taking histamine 2 receptor antagonists, a class of antihistamines, have a greater risk of developing Clostridium difficile infection, which can cause diarrhea. The risk was highest among hospitalized patients taking Study: Hay fever, asthma tied to lower CRC mortality risk
Having hay fever and asthma is associated with a modestly lower mortality risk among colorectal cancer patients, according to research that involved data from the Cancer Prevention Study I. However, the study team said it was unclear whether hay fever and asthma had any effect on colorectal cancer incidence. (4/3) Complying with health guidelines reduces mortality risk
Following guidelines for a healthy lifestyle may reduce the risk of death, according to a European study. People who adhered to health guidelines from the World Cancer Research Fund/American Institute for Cancer Research reduced their risk of death from respiratory http://www2.smartbrief.com/.=0942E7FC-7106-4E12-86CC-4511734432B7&sid=a50d4a85%2d51f0%2d424b%2d886c%2dec3a716b9d75[4/12/2013 12:39:23 PM] disease by 50%, from circulatory disease by 44% and from cancer by 20% when compared with people who were least compliant. (3/29) Diagnosis & Treatment
Study: HCV class prompts faster treatment, better response
Patients in a primary care-based hepatitis C education program started antiviral therapy more quickly and faced better odds of achieving a sustained virologic response than those who did not get the intervention. The class was facilitated by a nurse practitioner and covered symptoms, diagnosis, transmission and treatment. (4/3) Advanced rectal cancer protocol is promising, study shows
A novel treatment for advanced rectal cancer that includes short-term radiation and systemic chemotherapy followed by surgery shows promise and even curative potential for a condition that experts say currently lacks a standard of care. Dutch researchers reported that the novel protocol led to a two-year survival rate of 80%. (4/1) Other News
Policy Watch
FDA approves Eisai's Aciphex Sprinkle for pediatric GERD
The FDA has approved the use of Eisai's Aciphex Sprinkle delayed-release capsules, or rabeprazole sodium, for up to 12 weeks in children ages 1 to 11 with gastroesophageal reflux disease. The approval was based on results of a multicenter trial in which 81% of Aciphex- treated pediatric patients responded during the 12-week treatment period.
Cost of care to rise first, drop later under ACA, expert says
The Affordable Care Act should make medical care cheaper over time, although health care spending by insurance companies and the government will increase at first, says Henry Aaron, a health care expert at the Brookings Institution. "There is a lot of room to improve health care delivery, to bring down prices without undue loss of quality, and to encourage research into cost-reducing technology," he said. "The major obstacle will be the first couple Obama, GOP talks could lead to combining Medicare Parts A and B
http://www2.smartbrief.com/.=0942E7FC-7106-4E12-86CC-4511734432B7&sid=a50d4a85%2d51f0%2d424b%2d886c%2dec3a716b9d75[4/12/2013 12:39:23 PM] President Barack Obama is in talks with congressional Republicans about a deal that would combine Medicare Parts A and B in an effort to cut costs and prevent privatization of the program, The New York Times reports. The deal would combine Medicare's hospital and doctor coverage, which could increase beneficiaries' out-of-pocket costs but would also cap The Last Word
Understanding your digestive tract
How well do you know your gut? The American College of Gastroenterology has a increase your knowledge and understanding of digestive diseases and health.
SmartQuote
Yesterday is not ours to recover, but tomorrow is ours to win or lose." --Lyndon B. Johnson,
36th U.S. president
Mailing Address: , 555 11th ST NW, Suite 600, Washington, DC 20004 http://www2.smartbrief.com/.=0942E7FC-7106-4E12-86CC-4511734432B7&sid=a50d4a85%2d51f0%2d424b%2d886c%2dec3a716b9d75[4/12/2013 12:39:23 PM]

Source: http://www.bheofeastlake.com/advgastrotest/newsletter/NewsletterApr05.pdf

Microsoft word - lidingö.doc

Team: Lidingö sjukhem Syfte med deltagandet i Genombrott: Teammedlemmar: 1. Att skapa en meningsfull och harmonisk 2. Minska oro, förtvivlan och aggression hos Ssk, MS, Ed.D en utvald grupp boende. Population: Arbetet riktade sig primärt mot nio permanent Arbetsterapeut boende (6♂ & 3♀) på en demensavdelning Ssk2.lidingö@actica.se bestående av 30 boende totalt. Vas

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (impact)

Vol. 52, No. 4, April 2005, pp 1227–1236© 2005, American College of RheumatologySustained Benefits of Infliximab Therapy for Dermatologic andArticular Manifestations of Psoriatic ArthritisInfliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E. Antoni,1 Arthur Kavanaugh,2 Bruce Kirkham,3 Zuhre Tutuncu,2Gerd R. Burmester,4 Udo Schneider,4 Daniel E. Furst,5 Jerry M

Copyright © 2008-2018 All About Drugs